Company: VERA
Filing Date: 2025-12-10
Form Type: 424B5
Source: 0001193125-25-314244
Chunk: 78

Company: Vera Therapeutics, Inc.
Filing Date: 2025-12-10
Form: 424B5
Chunk 78
---
| • |     | if an event of default has occurred with regard to securities represented by that global security and has not 
 been cured or waived.                                                                                         |

27

The applicable prospectus supplement may also list additional situations for terminating a global security
that would apply only to the particular series of securities covered by the applicable prospectus supplement. When a global security terminates, the depositary, and neither we nor any applicable trustee, is responsible for deciding the names of the
institutions that will be the initial direct holders.

28

SELLING SECURITYHOLDERS

Selling securityholders are persons or entities that, directly or indirectly, have acquired or will from time to time acquire from us, our securities. If the
registration statement of which this prospectus forms a part is used by selling securityholders for the resale of any securities registered thereunder pursuant to a registration rights agreement between us and such selling securityholders or
otherwise, information about such selling securityholders, their beneficial ownership of our securities and their relationship with us will be set forth in a prospectus supplement, in a post-effective amendment or in filings we make with the SEC
under the Exchange Act that are incorporated by reference.

29

PLAN OF DISTRIBUTION We or selling securityholders may sell the securities covered hereby from time to time pursuant to underwritten public offerings, “at-the-market”offerings, direct sales to the public, negotiated transactions, block trades or a combination of these methods. A distribution of these securities offered by this prospectus may also be effected through the issuance of derivative securities, including without limitation, warrants. We or selling securityholders may sell the securities to or through underwriters or dealers, through agents, or directly to one or more purchasers. We or selling securityholders may distribute securities from time to time in one or more transactions:

| • |     | at a fixed price or prices, which may be changed; |

| • |     | at market prices prevailing at the time of sale; |

| • |     | at prices related to such prevailing market prices; or |

| • |     | at negotiated prices. |

A prospectus supplement or supplements (and any related free writing prospectus that we may authorize to be provided to you) will describe the terms of the offering of the securities, including, to the extent applicable:

| • |     | the name or names of any underwriters, dealers or agents, if any; |

| • |     | the name or names of the selling securityholders, if any; |

|